New combo aims for deep remission in lymphoma patients
NCT ID NCT05951959
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests a combination of three drugs (acalabrutinib, venetoclax, and rituximab) in people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood and keep it under control. Participants who respond well may stop some medications and be monitored, with the option to restart treatment if needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Hackensack, New Jersey, 07601, United States
-
Research Site
Stony Brook, New York, 11794, United States
-
Research Site
Cleveland, Ohio, 44195, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Kogarah, NSW 2217, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Sydney, 2109, Australia
-
Research Site
Porto Alegre, 90035-003, Brazil
-
Research Site
Rio de Janeiro, 22061-080, Brazil
-
Research Site
São Paulo, 01401-002, Brazil
-
Research Site
São Paulo, 05403-010, Brazil
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Vancouver, British Columbia, V5Z 4E6, Canada
-
Research Site
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Research Site
Barrie, Ontario, L4M 6M2, Canada
-
Research Site
Toronto, Ontario, M5G 2M9, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Gdynia, 81-519, Poland
-
Research Site
Krakow, 30-727, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Madrid, 28041, Spain
-
Research Site
Birmingham, B9 5SS, United Kingdom
-
Research Site
Gloucester, GL1 3NN, United Kingdom
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
Norwich, NR4 7UY, United Kingdom
-
Research Site
Nottingham, NG5 1PB, United Kingdom
-
Research Site
Plymouth, PL68BQ, United Kingdom
Conditions
Explore the condition pages connected to this study.